SCHEMBL15035294

SCHEMBL15035294

Cc1ccccc1Oc1cc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n(C2CC(=O)c3ccccc3C2)c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 2/20 0.55
CDK4 P11802 12/20 0.53
AURKA O14965 1/20 0.53
CCND1 P24385 11/20 0.52
CCND2 P30279 6/20 0.52
CCND3 P30281 6/20 0.52
CDK2 P24941 6/20 0.52
CCNA2 P20248 5/20 0.52
FGFR1 P11362 5/20 0.52
CCNE1 P24864 4/20 0.52
CDK1 P06493 2/20 0.52
CCNB1 P14635 2/20 0.52
NUAK1 O60285 2/20 0.52
MARK3 P27448 2/20 0.52
MARK2 Q7KZI7 2/20 0.52
MARK4 Q96L34 2/20 0.52
NUAK2 Q9H093 2/20 0.52
MARK1 Q9P0L2 2/20 0.52
CDK6 Q00534 2/20 0.52
PIK3CD O00329 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15041543 0.92 MAPK8 (0.62) MAPK8CDK4AURKACCND1CCND2
SCHEMBL15035392 0.90 CDK4 (0.47) MAPK8CDK4CCND1CCND2CCND3
SCHEMBL15035409 0.88 MAPK8 (0.54) MAPK8CDK4AURKACCND1CCND2
SCHEMBL15035511 0.82 MAPK8 (0.53) MAPK8CDK4AURKACCND1CCND2
SCHEMBL15041295 0.81 MAPK8 (0.49) MAPK8CDK4CCND1CCND2CCND3
SCHEMBL15041800 0.80 MAPK8 (0.61) MAPK8CDK4AURKACCND1CCND2
SCHEMBL5263907 0.77 CDK4 (0.82) CDK4AURKACCND1CCND2CCND3
SCHEMBL15034887 0.76 MAPK8 (0.52) MAPK8CDK4CCND1CCND2CCND3
SCHEMBL15035328 0.75 FGFR1 (0.45) MAPK8CDK4CCND1CCND2CCND3
SCHEMBL30597019 0.75 MAPK8 (0.74) MAPK8CDK4AURKACCND1CCND2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 MAPK8 493/4885CDK4 404/4885AURKA 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.